Character Biosciences has raised $93m in an oversubscribed Series B round to speed the clinical development of a pipeline of ...

Tempero Bio has raised $70m in Series B financing to advance its lead candidate TMP-301 through two clinical trials for ...

研究表明，重度抑郁症患者的mGluR5可用性显著低于健康对照者，伏硫西汀治疗后mGluR5可用性增加。 重度抑郁症（MDD）的治疗效果存在显著的个体差异 ...

In the context of SUDs, although there are no direct studies on astrocytic mGLUR5, evidence from related research suggests that it may be involved in regulating cue-associated drug memories.

[18 F]FPEB PET成像技术通过使用[18 F]FPEB示踪剂，能够特异性地标记和追踪大脑中mGluR5的可用性，这反映了其在神经传递中的活跃程度。 研究表明 ...

Recently, several pharmaceutical companies have begun to develop and test new, highly specific and potent drugs that antagonize mGluR5 signaling for the treatment of epilepsy and FXS, and these ...

为探究星形胶质细胞在慢性疼痛中对突触传递的影响机制，杭州城市大学的研究人员开展相关研究，发现 ACC 中星形胶质细胞 mGluR5 介导异常钙信号，加重雄性小鼠机械性异常疼痛。该成果为慢性疼痛治疗提供新靶点，值得科研人员一读。 在神经科学的奇妙世界 ...

Tempero Bio, Inc., a clinical-stage biopharmaceutical company developing transformative treatments for substance use disorders, today announced the closing of a $70 million Series B financing. The ...

Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Tempero ...